The FDA announced on Oct. 10, 2025, that Endo USA, Inc. is voluntarily recalling Everolimus Tablets 7.5mg due to failed impurity specifications. The recall affects 1,866 cartons distributed nationwide.
How to tell if you have it
- Brand: Endo USA
- Product: Everolimus Tablets 7.5mg
- NDC#: 49884-127-91
- Lot #: 550167301, Exp. Date NOV-25; 550167401, Exp. Date MAR-26; 550185101, Exp. Date MAR-26; 550205701, Exp. Date JUL-26
The hazard
The tablets are out of specification for impurity IP-C, according to the FDA.
Context
GovInfoNow's records show Endo USA, Inc. has had four other recalls since Nov. 18, 2024, including a March 13, 2026, recall of Buprenorphine Injection for crystallization risk and a Sept. 5, 2025, recall of Everolimus Tablets 5mg for impurity risks. Other recent recalls of similar products include Alembic Fesoterodine Tablets Recall (Dec. 16, 2025), Sun Pharmaceutical Fluocinolone Acetonide Solution Recall (Dec. 30, 2025), and Zydus Mirabegron 25mg Tablets Recall (Aug. 5, 2026).